Human cytomegalovirus-based immunotherapy to treat glioblastoma: Into the future

Glioblastoma multiforme (GBM) is the most aggressive brain tumor and median survival time with current therapies is only 14.6 mo. Although multiple immunotherapeutic strategies are being explored, efficacy remains poor. In order to improve immunotherapy for GBM, we propose to combine currently used...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Duinkerken, Sanne, van Kooyk, Yvette, Garcia-Vallejo, Juan J.
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2016
Assuntos:
Author's View
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5048761/
https://ncbi.nlm.nih.gov/pubmed/27757314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1214791
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://ncbi.nlm.nih.gov/pmc/articles/PMC5048761/
https://ncbi.nlm.nih.gov/pubmed/27757314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1214791

Registos relacionados